Trials / Completed
CompletedNCT02954172
Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC
Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 450 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, double blind, multicenter phase3 study .
Detailed description
A randomized, double blind, multicenter phase3 study in chemotherapy naive patients with stage IIIB,IV or recurrent NSCLC of non-squamous. the study will randomize about 436 patients at a 1:1 ratio to 2 treatment arms. The study is divided 4 phase, screening, combination treatment, maintenance and follow up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab in Combination With Paclitaxel/Carboplatin | Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg |
| DRUG | IBI305 in Combination with Paclitaxel/Carboplatin | Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg |
Timeline
- Start date
- 2016-11-28
- Primary completion
- 2018-10-19
- Completion
- 2019-11-12
- First posted
- 2016-11-03
- Last updated
- 2020-12-08
- Results posted
- 2020-12-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02954172. Inclusion in this directory is not an endorsement.